^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anti-SLAMF7 CAR T cells

    i
    Associations
    News

    Trials

    Company:
    National Cancer Center, University of Wuerzburg
    Drug class:
    CS-1-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma (NCT03958656)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/09/2021
    Initiation :
    06/13/2019
    Primary completion :
    10/13/2020
    Completion :
    01/19/2021
    SLAMF7
    |
    cyclophosphamide • fludarabine IV • Anti-SLAMF7 CAR T cells • rimiducid (AP1903)